CPHA Canvax

"This information was provided by the drug’s manufacturer when this drug product was approved for sale in Canada. It is designed for consumers and care givers. It is a summary of information about the drug and will not tell you everything about the drug. Contact your doctor or pharmacist if you have any questions about the drug." - Pfizer-BioNTech COVID-19 Vaccine (tozinameran) - Consumer Information


Web link

Pfizer-BioNTech COVID-19 Vaccine (tozinameran) - Consumer Information

Related Resources

Bookmark

Implementation Tool

Link

Category

Vaccine Safety and Development,Research and Development,Vaccine Safety,Vaccine Ingredients,Adverse Events Following Immunization (AEFI),Vaccine Safety,Monitoring and Surveillance,Outbreaks and Pandemics,COVID-19 Vaccine Safety and Development
Research and Development
Vaccine Safety
Vaccine Ingredients
Adverse Events Following Immunization (AEFI)
Vaccine Safety
Monitoring and Surveillance
Outbreaks and Pandemics
COVID-19

0 Comments

Using the comment box below, provide your feedback for this resource. Tell the immunization community how you used the resource, what worked, what didn't and the changes you made. The feedback provided will help inform the immunization community and improve upon the resource made available on CANVax.

All comments are anonymous. Submitted comments will be reviewed for approval by the CANVax team to ensure it meets content submission guidelines. Please note that although CANVax aims to approve comments in a timely manner, volume may result in delays.